| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 68 | 2025 | 325 | 16.210 |
Why?
|
| Antirheumatic Agents | 58 | 2024 | 213 | 14.270 |
Why?
|
| Gout | 18 | 2020 | 53 | 5.380 |
Why?
|
| Tumor Necrosis Factor-alpha | 22 | 2024 | 582 | 3.700 |
Why?
|
| Gout Suppressants | 11 | 2020 | 25 | 3.330 |
Why?
|
| Biological Products | 12 | 2024 | 94 | 3.040 |
Why?
|
| Registries | 39 | 2025 | 804 | 3.020 |
Why?
|
| Medication Adherence | 14 | 2018 | 254 | 2.950 |
Why?
|
| Rituximab | 4 | 2017 | 82 | 2.050 |
Why?
|
| Abatacept | 5 | 2024 | 63 | 2.020 |
Why?
|
| Severity of Illness Index | 30 | 2025 | 1448 | 1.910 |
Why?
|
| Rheumatology | 11 | 2020 | 65 | 1.870 |
Why?
|
| Middle Aged | 87 | 2025 | 16250 | 1.860 |
Why?
|
| Aged | 82 | 2025 | 13339 | 1.860 |
Why?
|
| Arthritis, Psoriatic | 6 | 2024 | 31 | 1.770 |
Why?
|
| Male | 101 | 2025 | 27550 | 1.660 |
Why?
|
| Practice Patterns, Physicians' | 11 | 2016 | 715 | 1.590 |
Why?
|
| Female | 102 | 2025 | 30886 | 1.550 |
Why?
|
| Treatment Outcome | 38 | 2024 | 5170 | 1.510 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2020 | 740 | 1.420 |
Why?
|
| Sjogren's Syndrome | 2 | 2020 | 26 | 1.360 |
Why?
|
| Humans | 133 | 2025 | 59426 | 1.360 |
Why?
|
| United States | 34 | 2024 | 7513 | 1.350 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 2 | 2019 | 6 | 1.260 |
Why?
|
| Disease Progression | 6 | 2025 | 1045 | 1.240 |
Why?
|
| Guideline Adherence | 6 | 2020 | 296 | 1.160 |
Why?
|
| Adult | 52 | 2024 | 15761 | 1.130 |
Why?
|
| Antibodies, Monoclonal | 8 | 2019 | 856 | 1.080 |
Why?
|
| Etanercept | 7 | 2019 | 31 | 1.060 |
Why?
|
| Adalimumab | 6 | 2019 | 36 | 1.020 |
Why?
|
| Methotrexate | 7 | 2022 | 76 | 0.990 |
Why?
|
| Pyrroles | 1 | 2024 | 50 | 0.940 |
Why?
|
| Piperidines | 1 | 2024 | 50 | 0.940 |
Why?
|
| Pyrimidines | 1 | 2024 | 121 | 0.910 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 170 | 0.870 |
Why?
|
| Rheumatologists | 4 | 2020 | 7 | 0.840 |
Why?
|
| Health Resources | 3 | 2019 | 88 | 0.830 |
Why?
|
| Prescription Drugs | 2 | 2013 | 50 | 0.820 |
Why?
|
| Prospective Studies | 13 | 2025 | 3096 | 0.790 |
Why?
|
| Churg-Strauss Syndrome | 3 | 2007 | 15 | 0.770 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2021 | 200 | 0.760 |
Why?
|
| Colchicine | 4 | 2020 | 27 | 0.750 |
Why?
|
| Attitude of Health Personnel | 3 | 2018 | 560 | 0.710 |
Why?
|
| Quality of Health Care | 4 | 2015 | 519 | 0.670 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 2327 | 0.650 |
Why?
|
| Cohort Studies | 20 | 2019 | 2443 | 0.650 |
Why?
|
| Health Maintenance Organizations | 5 | 2010 | 87 | 0.630 |
Why?
|
| Aged, 80 and over | 26 | 2018 | 5098 | 0.620 |
Why?
|
| Remission Induction | 9 | 2020 | 137 | 0.610 |
Why?
|
| Time Factors | 18 | 2021 | 3577 | 0.600 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2016 | 220 | 0.600 |
Why?
|
| Managed Care Programs | 3 | 2013 | 94 | 0.600 |
Why?
|
| Patient Compliance | 3 | 2010 | 371 | 0.600 |
Why?
|
| Certolizumab Pegol | 1 | 2018 | 2 | 0.600 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2017 | 35 | 0.590 |
Why?
|
| Inservice Training | 1 | 2018 | 84 | 0.570 |
Why?
|
| Drug Substitution | 2 | 2016 | 41 | 0.570 |
Why?
|
| Education, Medical, Continuing | 1 | 2018 | 98 | 0.560 |
Why?
|
| Depression | 5 | 2016 | 859 | 0.550 |
Why?
|
| Biological Factors | 1 | 2016 | 23 | 0.550 |
Why?
|
| Proportional Hazards Models | 11 | 2019 | 673 | 0.520 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2007 | 30 | 0.520 |
Why?
|
| Precision Medicine | 1 | 2017 | 103 | 0.510 |
Why?
|
| Osteoarthritis | 3 | 2008 | 130 | 0.500 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2020 | 118 | 0.500 |
Why?
|
| Sex Characteristics | 1 | 2017 | 196 | 0.500 |
Why?
|
| Drug Costs | 2 | 2013 | 59 | 0.490 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 448 | 0.490 |
Why?
|
| Bacterial Infections | 1 | 2016 | 138 | 0.490 |
Why?
|
| Ambulatory Care | 3 | 2014 | 300 | 0.460 |
Why?
|
| Practice Guidelines as Topic | 5 | 2016 | 704 | 0.450 |
Why?
|
| Prevalence | 9 | 2020 | 1284 | 0.440 |
Why?
|
| Immunoconjugates | 1 | 2013 | 84 | 0.430 |
Why?
|
| Psoriasis | 3 | 2020 | 51 | 0.430 |
Why?
|
| Arthritis, Juvenile | 1 | 2013 | 8 | 0.430 |
Why?
|
| Drug Therapy, Combination | 5 | 2024 | 432 | 0.430 |
Why?
|
| Algorithms | 6 | 2016 | 991 | 0.420 |
Why?
|
| Surveys and Questionnaires | 13 | 2020 | 2594 | 0.420 |
Why?
|
| Incidence | 11 | 2019 | 1237 | 0.410 |
Why?
|
| Culture | 1 | 2012 | 76 | 0.400 |
Why?
|
| Disease Management | 4 | 2020 | 220 | 0.390 |
Why?
|
| Asthma | 2 | 2007 | 419 | 0.390 |
Why?
|
| Multivariate Analysis | 8 | 2019 | 925 | 0.390 |
Why?
|
| Retrospective Studies | 13 | 2019 | 6001 | 0.380 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 6 | 2013 | 151 | 0.380 |
Why?
|
| Population Surveillance | 1 | 2012 | 205 | 0.370 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 311 | 0.370 |
Why?
|
| Health Expenditures | 1 | 2012 | 115 | 0.360 |
Why?
|
| Primary Health Care | 4 | 2016 | 649 | 0.360 |
Why?
|
| Hospitalization | 5 | 2016 | 1283 | 0.360 |
Why?
|
| Pain Measurement | 7 | 2019 | 330 | 0.360 |
Why?
|
| Self Care | 1 | 2012 | 211 | 0.350 |
Why?
|
| Spondylitis, Ankylosing | 2 | 2024 | 24 | 0.350 |
Why?
|
| Anticoagulants | 5 | 2012 | 485 | 0.350 |
Why?
|
| Chi-Square Distribution | 5 | 2019 | 401 | 0.350 |
Why?
|
| Nursing Homes | 7 | 2015 | 665 | 0.350 |
Why?
|
| Odds Ratio | 5 | 2023 | 773 | 0.340 |
Why?
|
| Uric Acid | 5 | 2019 | 49 | 0.340 |
Why?
|
| Age Factors | 9 | 2017 | 1516 | 0.330 |
Why?
|
| Hyperuricemia | 2 | 2019 | 8 | 0.330 |
Why?
|
| Glucocorticoids | 4 | 2023 | 172 | 0.330 |
Why?
|
| Health Surveys | 5 | 2017 | 306 | 0.330 |
Why?
|
| Arthroplasty, Replacement, Knee | 3 | 2016 | 125 | 0.320 |
Why?
|
| Linear Models | 3 | 2018 | 422 | 0.310 |
Why?
|
| Consensus | 3 | 2019 | 193 | 0.300 |
Why?
|
| Polyarteritis Nodosa | 1 | 2008 | 3 | 0.300 |
Why?
|
| Pancytopenia | 1 | 2008 | 7 | 0.300 |
Why?
|
| Propensity Score | 3 | 2018 | 134 | 0.300 |
Why?
|
| Insurance Claim Review | 2 | 2012 | 80 | 0.300 |
Why?
|
| Risk Factors | 9 | 2019 | 5010 | 0.300 |
Why?
|
| Spondylarthritis | 2 | 2020 | 42 | 0.300 |
Why?
|
| Disability Evaluation | 5 | 2015 | 216 | 0.290 |
Why?
|
| Rheumatic Diseases | 1 | 2008 | 41 | 0.290 |
Why?
|
| Accidents, Occupational | 1 | 2008 | 55 | 0.290 |
Why?
|
| Uricosuric Agents | 2 | 2020 | 2 | 0.290 |
Why?
|
| Myocardial Infarction | 3 | 2013 | 860 | 0.280 |
Why?
|
| Allopurinol | 4 | 2020 | 17 | 0.280 |
Why?
|
| Cross-Sectional Studies | 7 | 2017 | 2473 | 0.270 |
Why?
|
| Long-Term Care | 3 | 2008 | 174 | 0.270 |
Why?
|
| Symptom Assessment | 2 | 2017 | 39 | 0.270 |
Why?
|
| Databases, Factual | 10 | 2019 | 839 | 0.270 |
Why?
|
| Pain | 3 | 2020 | 405 | 0.270 |
Why?
|
| Logistic Models | 3 | 2019 | 1252 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2019 | 796 | 0.260 |
Why?
|
| Prognosis | 4 | 2018 | 1572 | 0.260 |
Why?
|
| Chronic Disease | 4 | 2015 | 736 | 0.260 |
Why?
|
| Health Status | 4 | 2020 | 449 | 0.250 |
Why?
|
| Predictive Value of Tests | 9 | 2015 | 1027 | 0.250 |
Why?
|
| Warfarin | 3 | 2012 | 109 | 0.250 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 237 | 0.240 |
Why?
|
| Research Design | 3 | 2024 | 567 | 0.240 |
Why?
|
| Adipokines | 1 | 2024 | 28 | 0.240 |
Why?
|
| Quality of Life | 4 | 2020 | 1118 | 0.240 |
Why?
|
| Glomerular Filtration Rate | 1 | 2025 | 95 | 0.230 |
Why?
|
| Cluster Analysis | 4 | 2023 | 250 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 387 | 0.230 |
Why?
|
| Feasibility Studies | 2 | 2018 | 527 | 0.230 |
Why?
|
| Knee Joint | 3 | 2016 | 284 | 0.230 |
Why?
|
| Arthralgia | 2 | 2015 | 59 | 0.230 |
Why?
|
| Massachusetts | 7 | 2014 | 2095 | 0.220 |
Why?
|
| Self Report | 3 | 2016 | 366 | 0.220 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2025 | 115 | 0.210 |
Why?
|
| Immunoglobulin G | 4 | 2012 | 452 | 0.210 |
Why?
|
| Delphi Technique | 3 | 2019 | 82 | 0.210 |
Why?
|
| Metabolic Syndrome | 1 | 2024 | 148 | 0.210 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1055 | 0.210 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 537 | 0.210 |
Why?
|
| Cost of Illness | 1 | 2024 | 155 | 0.210 |
Why?
|
| Neoplasms | 3 | 2022 | 1244 | 0.200 |
Why?
|
| Sex Factors | 5 | 2013 | 961 | 0.200 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2003 | 161 | 0.200 |
Why?
|
| Drug Administration Schedule | 5 | 2019 | 279 | 0.200 |
Why?
|
| Patient Selection | 2 | 2015 | 447 | 0.200 |
Why?
|
| Adolescent | 10 | 2016 | 5917 | 0.200 |
Why?
|
| Validation Studies as Topic | 2 | 2012 | 22 | 0.200 |
Why?
|
| Attitude | 1 | 2002 | 100 | 0.190 |
Why?
|
| Health Services | 1 | 2002 | 85 | 0.190 |
Why?
|
| Sulfasalazine | 1 | 2021 | 5 | 0.190 |
Why?
|
| Databases as Topic | 3 | 2007 | 53 | 0.190 |
Why?
|
| Obesity | 3 | 2022 | 1185 | 0.190 |
Why?
|
| North America | 3 | 2016 | 114 | 0.190 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 18 | 0.190 |
Why?
|
| Cardiac Catheterization | 1 | 2003 | 246 | 0.190 |
Why?
|
| Quality Improvement | 2 | 2017 | 425 | 0.190 |
Why?
|
| Antipsychotic Agents | 2 | 2015 | 312 | 0.190 |
Why?
|
| Coronary Artery Bypass | 1 | 2003 | 274 | 0.190 |
Why?
|
| Cardiovascular Diseases | 2 | 2022 | 819 | 0.180 |
Why?
|
| Homes for the Aged | 3 | 2012 | 164 | 0.180 |
Why?
|
| Joints | 3 | 2012 | 30 | 0.180 |
Why?
|
| Comorbidity | 3 | 2020 | 1090 | 0.180 |
Why?
|
| Osteoarthritis, Knee | 2 | 2016 | 383 | 0.180 |
Why?
|
| Delivery of Health Care | 2 | 2016 | 421 | 0.180 |
Why?
|
| Diphosphonates | 2 | 2010 | 35 | 0.180 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2012 | 61 | 0.170 |
Why?
|
| Women's Health | 1 | 2003 | 390 | 0.170 |
Why?
|
| Ustekinumab | 1 | 2020 | 5 | 0.170 |
Why?
|
| Infliximab | 4 | 2012 | 55 | 0.170 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 4 | 2012 | 51 | 0.170 |
Why?
|
| Monitoring, Physiologic | 2 | 2019 | 150 | 0.170 |
Why?
|
| Dermatologic Agents | 1 | 2019 | 21 | 0.170 |
Why?
|
| Medicare | 4 | 2023 | 600 | 0.170 |
Why?
|
| Fatigue | 1 | 2020 | 104 | 0.160 |
Why?
|
| Health Care Costs | 2 | 2016 | 204 | 0.160 |
Why?
|
| Crystal Arthropathies | 1 | 2019 | 1 | 0.160 |
Why?
|
| Physician-Patient Relations | 2 | 2020 | 392 | 0.160 |
Why?
|
| Longitudinal Studies | 6 | 2025 | 1225 | 0.160 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 86 | 0.150 |
Why?
|
| Terminology as Topic | 1 | 2019 | 137 | 0.150 |
Why?
|
| Diuretics | 2 | 2017 | 58 | 0.150 |
Why?
|
| Recurrence | 2 | 2017 | 577 | 0.150 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 782 | 0.150 |
Why?
|
| Health Care Surveys | 2 | 2013 | 279 | 0.150 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 207 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 303 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2017 | 84 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 141 | 0.140 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2008 | 48 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2016 | 58 | 0.130 |
Why?
|
| Nursing Staff | 2 | 2013 | 41 | 0.130 |
Why?
|
| Patients | 2 | 2013 | 103 | 0.120 |
Why?
|
| Drug Utilization | 2 | 2015 | 223 | 0.120 |
Why?
|
| Age Distribution | 2 | 2008 | 261 | 0.120 |
Why?
|
| Retreatment | 1 | 2015 | 45 | 0.120 |
Why?
|
| Medication Errors | 5 | 2012 | 116 | 0.120 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 23 | 0.120 |
Why?
|
| California | 4 | 2016 | 161 | 0.120 |
Why?
|
| Heart Failure | 2 | 2012 | 867 | 0.120 |
Why?
|
| Immunologic Factors | 2 | 2012 | 99 | 0.110 |
Why?
|
| Confidence Intervals | 2 | 2007 | 255 | 0.110 |
Why?
|
| Medicare Part B | 2 | 2012 | 10 | 0.110 |
Why?
|
| Sensitivity and Specificity | 5 | 2013 | 1094 | 0.110 |
Why?
|
| Office Visits | 1 | 2014 | 41 | 0.110 |
Why?
|
| Acute Disease | 2 | 2013 | 658 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2019 | 1912 | 0.110 |
Why?
|
| Medical Staff | 1 | 2013 | 14 | 0.110 |
Why?
|
| Arthroplasty, Replacement | 1 | 2013 | 15 | 0.110 |
Why?
|
| Osteoporosis | 2 | 2012 | 138 | 0.110 |
Why?
|
| Autoimmune Diseases | 2 | 2012 | 222 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2013 | 1838 | 0.110 |
Why?
|
| Administrative Personnel | 1 | 2013 | 33 | 0.110 |
Why?
|
| Connecticut | 4 | 2015 | 86 | 0.110 |
Why?
|
| Patient Discharge | 2 | 2014 | 479 | 0.100 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2013 | 24 | 0.100 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 43 | 0.100 |
Why?
|
| Seafood | 1 | 2012 | 18 | 0.100 |
Why?
|
| Dementia | 2 | 2013 | 247 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 172 | 0.100 |
Why?
|
| Perception | 1 | 2013 | 179 | 0.100 |
Why?
|
| Sampling Studies | 1 | 2012 | 66 | 0.100 |
Why?
|
| Sex Distribution | 2 | 2003 | 254 | 0.100 |
Why?
|
| Meat | 1 | 2012 | 44 | 0.100 |
Why?
|
| Medicare Part D | 1 | 2012 | 35 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2013 | 147 | 0.100 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2013 | 94 | 0.100 |
Why?
|
| Income | 1 | 2013 | 160 | 0.100 |
Why?
|
| Osteoporotic Fractures | 1 | 2012 | 32 | 0.100 |
Why?
|
| Hypertension | 1 | 2017 | 600 | 0.090 |
Why?
|
| Attitude to Health | 1 | 2013 | 275 | 0.090 |
Why?
|
| ROC Curve | 2 | 2009 | 258 | 0.090 |
Why?
|
| Life Style | 1 | 2013 | 328 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 158 | 0.090 |
Why?
|
| Qualitative Research | 2 | 2017 | 617 | 0.090 |
Why?
|
| Ischemic Attack, Transient | 1 | 2012 | 90 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2014 | 352 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 189 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 330 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2010 | 48 | 0.090 |
Why?
|
| Patient Satisfaction | 3 | 2013 | 411 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 299 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2011 | 134 | 0.080 |
Why?
|
| Patient Readmission | 1 | 2014 | 420 | 0.080 |
Why?
|
| Bone Resorption | 1 | 2010 | 49 | 0.080 |
Why?
|
| Probability | 1 | 2010 | 172 | 0.080 |
Why?
|
| Professional-Patient Relations | 1 | 2010 | 128 | 0.080 |
Why?
|
| Sulfinpyrazone | 1 | 2009 | 3 | 0.080 |
Why?
|
| Probenecid | 1 | 2009 | 6 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2010 | 139 | 0.080 |
Why?
|
| Child | 3 | 2013 | 4305 | 0.080 |
Why?
|
| Exercise | 1 | 2016 | 917 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2013 | 679 | 0.080 |
Why?
|
| Medical Order Entry Systems | 1 | 2008 | 45 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2010 | 490 | 0.080 |
Why?
|
| Job Description | 1 | 2008 | 22 | 0.070 |
Why?
|
| Risk | 3 | 2013 | 373 | 0.070 |
Why?
|
| New Hampshire | 1 | 2008 | 42 | 0.070 |
Why?
|
| Feeding Behavior | 1 | 2010 | 313 | 0.070 |
Why?
|
| Diet | 1 | 2012 | 634 | 0.070 |
Why?
|
| Leukotriene Antagonists | 1 | 2007 | 9 | 0.070 |
Why?
|
| Young Adult | 5 | 2016 | 4319 | 0.070 |
Why?
|
| Motivation | 1 | 2010 | 266 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2008 | 180 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 446 | 0.070 |
Why?
|
| International Normalized Ratio | 3 | 2012 | 34 | 0.070 |
Why?
|
| Stroke | 2 | 2013 | 1138 | 0.070 |
Why?
|
| Data Collection | 1 | 2008 | 384 | 0.070 |
Why?
|
| Diagnostic Errors | 1 | 2007 | 98 | 0.070 |
Why?
|
| Communication | 1 | 2011 | 555 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 154 | 0.060 |
Why?
|
| Disabled Persons | 1 | 2008 | 205 | 0.060 |
Why?
|
| Creatinine | 1 | 2006 | 123 | 0.060 |
Why?
|
| Physical Examination | 2 | 2016 | 103 | 0.060 |
Why?
|
| Total Quality Management | 1 | 2005 | 58 | 0.060 |
Why?
|
| Adiponectin | 1 | 2024 | 33 | 0.060 |
Why?
|
| Arthritis | 1 | 2005 | 50 | 0.060 |
Why?
|
| Leptin | 1 | 2024 | 78 | 0.060 |
Why?
|
| Mental Processes | 1 | 2023 | 18 | 0.060 |
Why?
|
| Concept Formation | 1 | 2023 | 16 | 0.050 |
Why?
|
| Drug Monitoring | 3 | 2012 | 96 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 298 | 0.050 |
Why?
|
| Prescriptions | 1 | 2023 | 33 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 115 | 0.050 |
Why?
|
| Group Practice | 1 | 2003 | 12 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2003 | 61 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 138 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 142 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2003 | 149 | 0.050 |
Why?
|
| Exercise Test | 1 | 2003 | 234 | 0.050 |
Why?
|
| Aspirin | 1 | 2003 | 170 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 161 | 0.050 |
Why?
|
| International Classification of Diseases | 2 | 2013 | 143 | 0.050 |
Why?
|
| Thrombolytic Therapy | 1 | 2003 | 180 | 0.050 |
Why?
|
| Internet | 1 | 2005 | 459 | 0.050 |
Why?
|
| Health Behavior | 1 | 2005 | 470 | 0.050 |
Why?
|
| Physician's Role | 1 | 2002 | 120 | 0.050 |
Why?
|
| Biomarkers | 2 | 2017 | 1197 | 0.050 |
Why?
|
| Thalidomide | 1 | 2020 | 33 | 0.040 |
Why?
|
| Febuxostat | 1 | 2020 | 2 | 0.040 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 13 | 0.040 |
Why?
|
| Echocardiography | 1 | 2003 | 459 | 0.040 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 29 | 0.040 |
Why?
|
| Biological Therapy | 1 | 2020 | 16 | 0.040 |
Why?
|
| Goals | 1 | 2020 | 90 | 0.040 |
Why?
|
| Interdisciplinary Placement | 1 | 2018 | 1 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2013 | 1306 | 0.040 |
Why?
|
| Medical Records | 2 | 2012 | 138 | 0.040 |
Why?
|
| Patient Preference | 1 | 2018 | 76 | 0.040 |
Why?
|
| Infant | 2 | 2013 | 1522 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2017 | 48 | 0.040 |
Why?
|
| Computers | 1 | 2016 | 48 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2016 | 66 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 55 | 0.030 |
Why?
|
| Knee Injuries | 1 | 2016 | 49 | 0.030 |
Why?
|
| Learning | 1 | 2017 | 171 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 220 | 0.030 |
Why?
|
| Accelerometry | 1 | 2016 | 59 | 0.030 |
Why?
|
| Health Facility Size | 1 | 2015 | 17 | 0.030 |
Why?
|
| Decision Making | 1 | 2018 | 391 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 885 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2014 | 46 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2015 | 105 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 100 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2015 | 242 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 24 | 0.030 |
Why?
|
| New Zealand | 1 | 2013 | 34 | 0.030 |
Why?
|
| New England | 2 | 2004 | 268 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2013 | 71 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 82 | 0.030 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2012 | 36 | 0.030 |
Why?
|
| Clinical Coding | 1 | 2013 | 43 | 0.030 |
Why?
|
| Inappropriate Prescribing | 1 | 2013 | 67 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2012 | 51 | 0.030 |
Why?
|
| Urban Population | 1 | 2013 | 182 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2013 | 191 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2013 | 201 | 0.020 |
Why?
|
| Health Services Research | 1 | 2013 | 270 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2013 | 261 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2012 | 89 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2013 | 115 | 0.020 |
Why?
|
| Mortality | 1 | 2012 | 160 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 483 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 453 | 0.020 |
Why?
|
| Bone Density | 1 | 2012 | 174 | 0.020 |
Why?
|
| Telephone | 1 | 2011 | 121 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 344 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1022 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 246 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 1096 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1548 | 0.020 |
Why?
|
| Physicians | 1 | 2013 | 437 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2007 | 268 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 68 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2005 | 113 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2006 | 141 | 0.010 |
Why?
|
| Self Concept | 1 | 2005 | 103 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2004 | 35 | 0.010 |
Why?
|
| Ambulatory Care Facilities | 1 | 2004 | 102 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2004 | 95 | 0.010 |
Why?
|
| Patient Participation | 1 | 2005 | 211 | 0.010 |
Why?
|
| Medicare Part C | 1 | 2003 | 15 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 903 | 0.010 |
Why?
|
| Software | 1 | 2005 | 367 | 0.010 |
Why?
|
| Pharmaceutical Preparations | 1 | 2003 | 122 | 0.010 |
Why?
|